newsfilter
← Latest News
GlobeNewswire·

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Characterizing the novel neuropharmacology of CY6463's NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic